Altimmune(ALT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The net loss for Q4 2025 was $27.4 million or $0.27 per share, compared to a net loss of $23.2 million or $0.33 per share in Q4 2024, indicating an increase in losses year-over-year [31][32] - R&D expenses in Q4 2025 were $18.4 million, down from $19.8 million in the same period of 2024, primarily due to the completion of the Phase 2b trial [30] - G&A expenses increased to $10.5 million in Q4 2025 from $5.1 million in Q4 2024, driven by one-time charges related to executive transition and increased professional fees [31] Business Line Data and Key Metrics Changes - The company is focused on advancing pemvidutide for liver diseases, particularly MASH, with promising results from Phase 2 trials showing early MASH resolution and anti-fibrotic activity [9][16] - The Phase 2 AUD trial completed enrollment ahead of schedule, with top-line data expected in Q3 2026 [14][23] - The Phase 2 trial assessing pemvidutide in ALD is expected to complete enrollment in 2026 [14] Market Data and Key Metrics Changes - Market research indicated significant unmet needs among MASH patients, particularly for those who have discontinued semaglutide due to tolerability issues [25][26] - Physicians expressed a high unmet need for therapies that preserve lean muscle mass in MASH patients, highlighting the potential competitive advantage of pemvidutide [25][26] Company Strategy and Development Direction - The company aims to strengthen its foundation for the advancement of pemvidutide and has enhanced its leadership team with expertise in liver disease and late-stage clinical development [11] - A $75 million capital raise was completed to support the planned initiation of the Phase 3 trial for pemvidutide [12] - The company is preparing for a pivotal Phase 3 trial with a focus on MASH, aligning with FDA guidance on trial design and endpoints [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pemvidutide to address significant unmet needs in liver diseases, emphasizing its dual mechanism of action [6][9] - The company is committed to creating long-term value for shareholders while advancing its clinical programs [35] Other Important Information - The company reported total cash of $274 million at year-end 2025, with a pro forma cash position of approximately $340 million after recent capital raises [32][33] - The Phase 3 trial will enroll approximately 1,800 patients globally, with a focus on both biopsy-confirmed and non-invasive test-assessed MASH patients [21][22] Q&A Session Summary Question: Can the FDA's new single pivotal framework save costs for the Phase 3 trial? - Management indicated that the current approach remains unchanged and the path for approval is through a single trial for accelerated approval [36][38] Question: What are the statistical plans for the Phase 3 trial? - The study is powered for two primary endpoints, with a sample size of around 990 patients, ensuring sufficient power for approval [39][41] Question: What is the FDA's stance on using non-invasive tests as registrational endpoints? - The FDA deemed it premature to consider non-invasive tests for approval, focusing instead on biopsy-driven endpoints [47][48] Question: What are the key elements locked in for the Phase 3 protocol? - The protocol is nearing finalization, with critical elements like sample size and primary endpoints aligned, while finalizing biopsy details [86][87] Question: How will the company proceed with the AUD and ALD trials? - The company plans to assess AUD data and make decisions without waiting for ALD results, focusing on immediate next steps [93]